Bristol Metaglip Launch Set For November; Third Metformin Line-Extension
Executive Summary
Bristol-Myers Squibb's antidiabetic Metaglip (glipizide/metformin) is expected to launch in November following its Oct. 21 approval
You may also be interested in...
Bristol Puerto Rico Plant Cited By FDA; Firm Upgrades Out-Of-Spec Standards
Bristol-Myers Squibb has updated standards for handling out-of-specification results at all of its pharmaceutical manufacturing facilities, the company told FDA in response to a recent warning letter issued after an inspection of its Mayaguez, Puerto Rico plant
Bristol Puerto Rico Plant Cited By FDA; Firm Upgrades Out-Of-Spec Standards
Bristol-Myers Squibb has updated standards for handling out-of-specification results at all of its pharmaceutical manufacturing facilities, the company told FDA in response to a recent warning letter issued after an inspection of its Mayaguez, Puerto Rico plant
Bristol Metaglip (correction)
Bristol-Myers Squibb's Metaglip (glipizide/metformin) clears FDA Oct. 21. "The Pink Sheet" (1Oct. 28, p. 13) incorrectly reported the approval date...